Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Targeting microenvironment-mediated resistance in leukemias: Phase I trial of mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor/g-CSF/sorafenib
In some embodiments, the formulation contains 8-12 mg/ml cagrilintide
4 ESCC remains the predominant histological subtype, accounting for more than 80% of EC cases in the Chinese population
Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2)
US$ 29.81
US$ 25.30
US$ 26.54
US$ 27.38
US$ 25.25
US$ 21.79
US$ 23.35
US$ 20.83
US$ 26.45
US$ 27.40
US$ 26.45
US$ 29.66
US$ 24.60
